Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the complexities of attracting and retaining talent in the highly competitive Chinese market.
In 2014, my first angel investor actually told me, "91 percent of these kinds of research programs fail. I am not investing in SIMR because I believe in your products, I am investing in SIMR because I believe in you. I believe that you can eventually develop a successful product."
